Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Accuray reports strong Q1 2023 earnings and focuses on global expansion

Accuray's Q1 2023 earnings call highlighted strong financial performance, with significant revenue growth and increased system orders. The company is focused on driving profitability expansion and expanding patient access to its technologies worldwide. While facing challenges in managing backlog and addressing performance in China, Accuray is actively pursuing opportunities for margin expansion and business growth.

Accuray delivers record Q2 performance, eyes growth opportunities ahead

Accuray's Q2 2023 performance highlighted record system deliveries and strong order growth, with a focus on radiation oncology services.
Despite challenges in revenue decline and backlog, strategic wins and progress in key regions position the company for future growth.
Opportunities lie in market expansion in the Americas, strategic wins in key regions, and advancements in China.
Maintaining growth momentum, addressing revenue challenges, and capitalizing on opportunities are key focus areas for Accuray.

Accuray reports strong Q3 earnings, eyes global expansion and partnerships

Accuray's Q3 2023 earnings call showcased robust financial performance, strategic initiatives to drive profitability, and a commitment to global expansion. Despite challenges in product positioning and market competition, the company's focus on innovation and partnerships positions it well for future growth and market leadership.

Accuray reports 8% revenue growth, eyes margin expansion and growth

Accuray's Q4 2023 performance showed revenue growth, strong demand for Radixact, and strategic order wins. While facing challenges in product margins and supply chain, the company aims for margin expansion and growth opportunities in the second half of FY '24. Implementation of a new ERP system is expected to drive operational efficiencies and profitability insights.

Accuray reports strong Q1 earnings, eyes growth in China and India

Accuray delivered a robust Q1 performance with revenue and EBITDA growth, backed by strategic wins in key markets like China and India. The company's focus on new product innovations and cost optimization efforts contributed to its positive results. While challenges related to inflation exist, Accuray remains optimistic about reimbursement changes and market opportunities.

Accuray reports strong Q2 performance with growth opportunities ahead

Accuray's Q2 2024 showcased robust order growth, service revenue increase, and global demand strength. The company is focused on margin expansion and new product market clearances for future growth.

Accuray faces challenges in Q3 2024 but remains optimistic

Accuray's Q3 2024 performance was impacted by challenges but showed resilience with global order growth and strategic focus on long-term goals. Despite revised guidance, the company remains optimistic about future growth drivers and is prepared for gradual recovery post-COVID.

Accuray reports robust Q1 performance and raises FY '25 guidance

Accuray's Q1 2025 performance reflects strong revenue growth, margin expansion efforts, and positive market reception for its innovative products and services.
While facing challenges in certain markets and regulatory timelines, the company remains optimistic about future revenue trends and growth opportunities globally.
By raising its revenue guidance and focusing on operational efficiency, Accuray aims to capitalize on market opportunities and navigate potential challenges effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. It develops, manufactures, sells, and supports medical solutions. The company was founded by John R. Adler in 1990 and is headquartered in Madison, WI.

Accuray (ARAY) announces an agreement with TrueNorth to provide radiation oncology departments with third-party support designed to improve their department's capabilities.

Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments

MADISON, Wis. , June 20, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party support designed to enhance their department's capabilities.

Accuray and TrueNorth Medical Physics Sign Agreement to Provide Radiation Oncology Support Intended to Advance Cancer Care for More Patients

Altus Power

BigBear.ai Holdings

By now, you know the dangers of “millionaire-maker penny stocks.” Whenever we even mention a penny stock, we add a disclaimer at the end of articles.

3 Millionaire-Maker Penny Stocks Set to Surge by 1,000%: June Edition

Accuray (ARAY) announces the approval of the Accuray Precision Treatment Planning System by the Chinese Medical Products Administration.

Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA

MADISON, Wis. , June 12, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the Accuray Precision ® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA).

Accuray Announces Approval of the Accuray Precision® Treatment Planning System by China's National Medical Products Administration

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?

Accuray (ARAY) Up 2% Since Last Earnings Report: Can It Continue?

ASGN

B&G Foods

ASGN, ARAY and BGS have been added to the Zacks Rank #5 (Strong Sell) List on May 31, 2023.

New Strong Sell Stocks for May 31st

Brenntag SE

3D Systems

DDD, ARAY and BNTGY have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2023.

New Strong Sell Stocks for May 24th

MADISON, Wis. , May 22, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2024.

Accuray to Participate in the Jefferies Global Healthcare Conference 2024

Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.

Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts

Accuray Incorporated (NASDAQ:ARAY ) Q3 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Jesse Chew - SVP and Chief Legal Officer Suzanne Winter - President and CEO Ali Pervaiz - CFO Conference Call Participants Young Li - Jefferies Brooks O'Neil - Lake Street Jason Wittes - ROTH MKM Operator Good afternoon, and welcome to the Accuray conference call to review financial results for the third quarter of fiscal year 2024 which ended March 31 of 2024. All participants will be in listen-only mode.

Accuray Incorporated (ARAY) Q3 2024 Earnings Call Transcript

Accuray (ARAY) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.01 per share a year ago.

Accuray (ARAY) Reports Q3 Loss, Lags Revenue Estimates

MADISON, Wis. , May 1, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter and nine-months ended March 31, 2024.

Accuray Reports Fiscal 2024 Third Quarter Financial Results

Celebrates 30 Years of Innovation Through Collaboration and the Development of Technologies That Have Helped Set the Standard of Care for the Industry MADISON, Wis. , April 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024.

Accuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024

The new center is the most recent addition to the company's existing training hubs in Madison, Wisconsin (U.S.), Tokyo, Japan and Tianjin, China  Each facility offers a range of educational opportunities designed to advance patient care using the Accuray CyberKnife® and Radixact® Systems MADISON, Wis., April 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that as part of its commitment to advancing patient care the company has opened a new training center in Genolier, Switzerland, that will serve as the European education hub for radiosurgery and radiotherapy product training, and sharing of best practices and innovative techniques using the latest model Accuray CyberKnife ® and Radixact ® Radiation Treatment Delivery Systems and Accuray Precision ® Treatment Planning System.

Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland

MADISON, Wis. , April 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m.

Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024

Despite management guidance that points to significant revenue acceleration in the next two quarters, Accuray shares have languished. Market skepticism can be tied in part to the company's track record - despite multiple efforts to improve its portfolio and go-to-market strategy, market share growth has been very modest. The company's entry into China's Type B market could be its last best chance to change the narrative - meaningful share in a $600M/year market should be transformative.

Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp

Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.

Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment

Data Also Underscores Potential Benefits of CyberKnife System Sub-millimeter Accuracy in Preserving Quality of Life after Treatment for Prostate Cancer MADISON, Wis. , March 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife ® System in the treatment of high-risk and recurrent prostate cancer.

New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System

Company to Take Part in Fireside Chat Monday, March 18, 2024 at 12:30pm PST / 3:30pm EST MADISON, Wis. , March 4, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 36th Annual Roth Conference.

Accuray Incorporated to Speak at 36th Annual Roth Conference

Accuray (ARAY) Up 1.6% Since Last Earnings Report: Can It Continue?

Company to Take Part in Fireside Chat Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST MADISON, Wis. , Feb. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference taking place March 12-13, 2024.

Accuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

B2Gold

ChargePoint Holdings

Cipher Mining

VAALCO Energy

Wag! Group Co

Planet Labs

While most financial advisors will probably steer you away from under $5 stocks, they have their benefits. Just like in football – the American kind – you can't just run up the gut.

7 Screaming Stock Buys for Under $5

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is a center of excellence and recognized leader in the treatment of cancer in the province of Quebec The Radixact System is equipped with ClearRT™ and Synchrony®, advanced technologies designed to improve treatment outcomes for more patients each day MADISON, Wis. , Feb. 13, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the team at Quebec's Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is the first in Canada to treat cancer patients using the company's Radixact ® radiation therapy delivery system.

News for Accuray Stock (ARAY)